These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 36760031)

  • 21. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
    Schettini F; Giudici F; Giuliano M; Cristofanilli M; Arpino G; Del Mastro L; Puglisi F; De Placido S; Paris I; De Placido P; Venturini S; De Laurentis M; Conte P; Juric D; Llombart-Cussac A; Pusztai L; Prat A; Jerusalem G; Di Leo A; Generali D
    J Natl Cancer Inst; 2020 Nov; 112(11):1089-1097. PubMed ID: 32407488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
    Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
    ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.
    Jia L; Peng J; Sun N; Chen H; Liu Z; Zhao W; Zhang Q; Li L
    BMC Cancer; 2024 Jul; 24(1):850. PubMed ID: 39020297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
    Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
    Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
    Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
    Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy analysis of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 inhibitor treatment in hormone receptor positive/human epidermal growth factor receptor 2-low metastatic breast cancer].
    Liu B; Yuan Y; Li F; Li JB; Bian L; Wang T; Zhang SH; Jiang ZF
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1507-1513. PubMed ID: 38706058
    [No Abstract]   [Full Text] [Related]  

  • 32. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    Howie LJ; Singh H; Bloomquist E; Wedam S; Amiri-Kordestani L; Tang S; Sridhara R; Sanchez J; Prowell TM; Kluetz PG; King-Kallimanis BL; Gao JJ; Ibrahim A; Goldberg KB; Theoret M; Pazdur R; Beaver JA
    J Clin Oncol; 2019 Dec; 37(36):3475-3483. PubMed ID: 31560580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.
    Hui R; de Boer R; Lim E; Yeo B; Lynch J
    Asia Pac J Clin Oncol; 2021 Jan; 17 Suppl 1():3-14. PubMed ID: 33506626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
    Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
    JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
    Meegdes M; Geurts SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Teeuwen NJA; de Boer M; Tjan-Heijnen VCG
    Int J Cancer; 2022 Jan; 150(1):124-131. PubMed ID: 34460112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Önder T; Ateş Ö; Öner İ; Karaçin C
    Clin Breast Cancer; 2024 Aug; 24(6):519-526. PubMed ID: 38879437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
    Dai Q; Wang Y; Liao M; Chen H
    Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
    Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
    Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
    Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL
    J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
    Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.